TY - JOUR
T1 - US Cutaneous Oncodermatology Management (USCOM)
T2 - A Practical Algorithm
AU - Lacouture, Mario E.
AU - Choi, Jennifer
AU - Ho, Alice
AU - Leventhal, Jonathan
AU - McLellan, Beth N.
AU - Andriessen, Anneke
AU - Sauder, Maxwell B.
AU - Mitchell, Edith
N1 - Publisher Copyright:
© 2021 Journal of Drugs in Dermatology. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Background: An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients' quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients' and survivors' quality of life by offering tools for preventing and managing cAEs. Methods: An algorithm was designed to reduce the incidence of cAEs, treat cAEs, and maintain healthy skin using general measures and over-the-counter agents to support all healthcare providers treating oncology patients, including physicians, nurses, pharmacists, and advanced providers. The panel used a modified Delphi approach, developed, discussed, and reached a consensus on statements and an evidence-based algorithm. Do Not Copy Results: maintenance The using USCOM skincare algorithm measures includes before, education during, Penalties and on after cAEs cancer for treatment. patients Apply and A skincare clinicians regimen supporting including prevention, hygiene, treatment, moisturization, and and sun protection products should be safe and effective in helping to minimize cAEs and improving skin conditions such as erythema, xerosis, pruritus, and photosensitivity. The number and quality of studies evaluating skincare formulations and regimens for cAEs are increasing, but the evidence on the benefits of specific formulations is still scarce. Conclusions:The algorithm focuses on general measures and skincare to prevent or reduce the severity of cAEs. Increased awareness of cAEs by the multidisciplinary team treating and guiding the cancer patient throughout their care may improve patient outcomes.
AB - Background: An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients' quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients' and survivors' quality of life by offering tools for preventing and managing cAEs. Methods: An algorithm was designed to reduce the incidence of cAEs, treat cAEs, and maintain healthy skin using general measures and over-the-counter agents to support all healthcare providers treating oncology patients, including physicians, nurses, pharmacists, and advanced providers. The panel used a modified Delphi approach, developed, discussed, and reached a consensus on statements and an evidence-based algorithm. Do Not Copy Results: maintenance The using USCOM skincare algorithm measures includes before, education during, Penalties and on after cAEs cancer for treatment. patients Apply and A skincare clinicians regimen supporting including prevention, hygiene, treatment, moisturization, and and sun protection products should be safe and effective in helping to minimize cAEs and improving skin conditions such as erythema, xerosis, pruritus, and photosensitivity. The number and quality of studies evaluating skincare formulations and regimens for cAEs are increasing, but the evidence on the benefits of specific formulations is still scarce. Conclusions:The algorithm focuses on general measures and skincare to prevent or reduce the severity of cAEs. Increased awareness of cAEs by the multidisciplinary team treating and guiding the cancer patient throughout their care may improve patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85115920476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115920476&partnerID=8YFLogxK
U2 - 10.36849/JDD.6229
DO - 10.36849/JDD.6229
M3 - Article
C2 - 34491030
AN - SCOPUS:85115920476
SN - 1545-9616
VL - 20
SP - S3-S18
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 9
ER -